Novo Nordisk A/S (NVO) Competitors

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Do analysts prefer NVO or NVS?

Novo Nordisk A/S currently has a consensus price target of $144.50, indicating a potential upside of 37.27%. Novartis has a consensus price target of $121.50, indicating a potential upside of 17.86%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Novartis	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.89

Which has more risk & volatility, NVO or NVS?

Novo Nordisk A/S has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Which has preferable valuation and earnings, NVO or NVS?

Novartis has lower revenue, but higher earnings than Novo Nordisk A/S. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$270.58B	1.75	$12.15B	$3.09	34.07
Novartis	$45.44B	4.64	$14.85B	$8.61	11.97

Is NVO or NVS a better dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.72 per share and has a dividend yield of 0.7%. Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.4%. Novo Nordisk A/S pays out 23.3% of its earnings in the form of a dividend. Novartis pays out 28.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Does the MarketBeat Community believe in NVO or NVS?

Novartis received 108 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. However, 61.64% of users gave Novo Nordisk A/S an outperform vote while only 61.01% of users gave Novartis an outperform vote.

Company	Underperform	Outperform
Novo Nordisk A/S	Outperform Votes 421 61.64%	Underperform Votes 262 38.36%
Novartis	Outperform Votes 529 61.01%	Underperform Votes 338 38.99%

Is NVO or NVS more profitable?

Novartis has a net margin of 35.96% compared to Novo Nordisk A/S's net margin of 35.03%. Novo Nordisk A/S's return on equity of 86.32% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.03%	86.32%	27.42%
Novartis	35.96%	34.80%	15.13%

Do institutionals & insiders have more ownership in NVO or NVS?

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media favor NVO or NVS?

In the previous week, Novo Nordisk A/S had 15 more articles in the media than Novartis. MarketBeat recorded 38 mentions for Novo Nordisk A/S and 23 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.91 beat Novartis' score of 0.61 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	22 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats Novartis on 12 of the 20 factors compared between the two stocks.